Comparative efficacy of escitalopram in the treatment of major depressive disorder

QR Code

Comparative efficacy of escitalopram in the treatment of major depressive disorder

Mazen K Ali, Raymond W LamDepartment of Psychiatry, University of British Columbia, and Mood Disorders Centre, University of British Columbia Hospital, Vancouver, CanadaBackground: Escitalopram is an allosteric selective serotonin reuptake inhibitor (SSRI) with some indication of superior efficacy i...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Mazen K Ali, Raymond W Lam
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2011
Sujets:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/202c6de51be34c86b4a2ce40c0eec2b4
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Efficacy and safety of generic escitalopram (Lexacure®) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study
par: Jeong JH, et autres
Publié: (2015)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
par: Maneeton B, et autres
Publié: (2018)

The therapeutic potential of escitalopram in the treatment of panic disorder
par: Mark H Townsend, et autres
Publié: (2007)

Desvenlafaxine in the treatment of major depressive disorder
par: Maria Teresa C Lourenco1, et autres
Publié: (2009)

Lower serum brain-derived neurotrophic factor levels are associated with failure to achieve remission in patients with major depression after escitalopram treatment
par: Lee BH, et autres
Publié: (2014)

Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
par: Zhang XF, et autres
Publié: (2015)

Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population
par: Jiang KD, et autres
Publié: (2017)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
par: Huang J, et autres
Publié: (2018)

Augmentation treatment in major depressive disorder: focus on aripiprazole
par: J Craig Nelson, et autres
Publié: (2008)

Levomilnacipran for the treatment of major depressive disorder: a review
par: Asnis GA, et autres
Publié: (2015)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
par: Alvarez E, et autres
Publié: (2014)

Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder
par: Aoki A, et autres
Publié: (2014)

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies
par: Han Y, et autres
Publié: (2016)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
par: Kishi T, et autres
Publié: (2017)

Psychiatric comorbidities in patients with major depressive disorder
par: Thaipisuttikul P, et autres
Publié: (2014)

Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study
par: Dell&#39;Osso B, et autres
Publié: (2013)

Mitochondrial dysfunction, oxidative stress, and major depressive disorder
par: Tobe EH
Publié: (2013)

Safety of escitalopram in pregnancy: a case series
par: Bellantuono C, et autres
Publié: (2013)

Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study
par: Gabriel A
Publié: (2013)

Major depressive disorder: mechanism-based prescribing for personalized medicine
par: Saltiel PF, et autres
Publié: (2015)

Anatomical and functional brain abnormalities in unmedicated major depressive disorder
par: Yang X, et autres
Publié: (2015)

Transcranial magnetic stimulation for the treatment of major depression
par: Janicak PG, et autres
Publié: (2015)

Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report
par: Kitaichi Y, et autres
Publié: (2013)

Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
par: Singh M, et autres
Publié: (2012)

The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients
par: Koshino Y, et autres
Publié: (2013)

New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
par: Bernhard T Baune
Publié: (2008)

Serotonin syndrome induced by the readministration of escitalopram after a short-term interruption in an elderly woman with depression: a case report
par: Sato Y, et autres
Publié: (2015)

Major depressive disorders in chronic hemodialysis patients in Nazareth: identification and assessment
par: Armaly Z, et autres
Publié: (2012)

Getting the balance right: Established and emerging therapies for major depressive disorders
par: Bojana Perovic, et autres
Publié: (2010)

Is placebo useful in the treatment of major depression in clinical practice?
par: Marchesi C, et autres
Publié: (2013)

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole
par: Marty Hinz, et autres
Publié: (2010)

Effects of escitalopram with a Chinese traditional compound Jiuweizhenxin-keli on mismatch negativity and P50 in patients with major depressive disorders
par: Kuang W, et autres
Publié: (2016)

A review of electroencephalographic changes in diabetes mellitus in relation to major depressive disorder
par: Baskaran A, et autres
Publié: (2013)

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
par: Kamijima K, et autres
Publié: (2013)

Radioelectric brain stimulation in the treatment of generalized anxiety disorder with comorbid major depression in a psychiatric hospital: a pilot study
par: Fontani V, et autres
Publié: (2011)

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
par: Huang Q, et autres
Publié: (2016)

Association between toll-like receptor 4 expression and symptoms of major depressive disorder
par: Wu MK, et autres
Publié: (2015)

Neutrophil–lymphocyte ratio in patients with major depressive disorder undergoing no pharmacological therapy
par: Demir S, et autres
Publié: (2015)

Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study
par: Novick D, et autres
Publié: (2015)

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression [Corrigendum]
par: Kamijima K, et autres
Publié: (2013)